Overview

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.
Phase:
Phase 3
Details
Lead Sponsor:
Ambrilia Biopharma, Inc.
Treatments:
Octreotide